RxDoctor Payments Data

Haley Spencer

Physician Assistant · Searcy, ARNPI 1194281188

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 98.9% of the total across 343 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 17 manufacturers reported payments, led by Amgen at 31.5% of the total. Among physician assistant clinicians in AR with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,685in general payments, 2019–2025

Across 343 payments — averaging $16.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$2K
  • UCB, Inc.$984
  • Johnson & Johnson$600
  • Mallinckrodt Hospital Products Inc.$460
  • AbbVie$432
  • GSK$430
  • plus $988 from 11 others

What the payments were for

  • Food & beverage$5,62599%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,685 in reported general payments places this provider in the 90th percentile of 451 physician assistant providers in Arkansas.

See all physician assistant providers in Arkansas

Medicare billing

Part B allowed, 2024
$3,737
Medicare patients
47
Services billed
50

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept49$437,213
Humira(Cf) PenAdalimumab38$274,230
TavneosAvacopan11$178,478
MethotrexateMethotrexate Sodium357$9,136
Hydroxychloroquine Sulfate194$8,690
Colchicine59$5,053
Mycophenolate Mofetil15$3,378
Celecoxib32$2,304
Azathioprine40$1,958
Leucovorin Calcium37$1,933
Diclofenac Sodium85$1,801
Sulfasalazine28$886
Meloxicam80$497
Sulfasalazine DrSulfasalazine18$465
Allopurinol43$413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenTavneos$1,791$178,47811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 451 physician assistant providers in Arkansas.

Other physician assistant in Searcy

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →